A Second Look: Discussing Karyopharm's Subgroup Analysis SIENDO Study in Patients with TP53 Wild Type Endometrial Cancer for Selinexor as Maintenance Therapy

Executed on:May 9, 2023 3:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: MSKCCAttending physician at MSKCC, Gynecologic Oncologist & Early Drug Development Specialist
Primary interest is caring for women with ovarian cancer, endometrial cancer, cervical cancer, and other gynecologic cancers and researching these diseases.
Served on the steering committee for the Society for Gynecologic Oncology and on the medical oncology committee of the Gynecologic Oncology Group.

Interview Goal

This conversation will focus on the potential of Karyopharm's  selinexor as a maintenance therapy for TP53 WT endometrial cancer patients.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.